Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 4, 2013

Primary Completion Date

September 14, 2018

Study Completion Date

March 17, 2026

Conditions
Recurrent NeuroblastomaRefractory Neuroblastoma
Interventions
BIOLOGICAL

Dinutuximab

Given IV

DRUG

Isotretinoin

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (15)

19104

Children's Hospital of Philadelphia, Philadelphia

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

30329

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

C S Mott Children's Hospital, Ann Arbor

60637

University of Chicago Comer Children's Hospital, Chicago

76104

Cook Children's Medical Center, Fort Worth

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

94143

UCSF Medical Center-Parnassus, San Francisco

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

98105

Seattle Children's Hospital, Seattle

02115

Boston Children's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH